What is the recommended dosing and administration protocol for 3% sodium chloride (hypertonic saline) in an adult with high‑grade (grade 3‑4) encephalopathy and suspected raised intracranial pressure?

How to Use Hypertonic Saline for High-Grade Encephalopathy with Suspected Raised Intracranial Pressure

For an adult with grade 3-4 encephalopathy and suspected raised intracranial pressure, administer 3% sodium chloride as a continuous infusion targeting a serum sodium of 145-155 mEq/L, or give bolus doses of 250 mOsm (approximately 250-300 mL of 3% NaCl) infused over 15-20 minutes to acutely lower ICP. 1

Dosing Protocol

For Acute ICP Crisis or Herniation Signs

• Bolus dosing: Administer 250 mOsm of hypertonic saline over 15-20 minutes 1
  • This translates to approximately 250-300 mL of 3% sodium chloride
  • Alternative: 1.4 mL/kg of 3% NaCl has been shown effective 2
  • Expect ICP reduction within 10-15 minutes, with maximum effect lasting 2-4 hours 1

For Sustained ICP Management

• Continuous infusion: Use 3% sodium chloride targeting serum sodium of 145-155 mEq/L 3
• This approach is particularly effective in acute liver failure and pediatric traumatic brain injury 3
• Monitor serum sodium and osmolarity regularly to maintain target range

Administration Route

Peripheral IV administration is safe for 3% hypertonic saline, contrary to common misconceptions 4, 5:

• Rates up to 999 mL/h have been safely administered peripherally without extravasation or phlebitis 4
• An 18-gauge IV in the antecubital fossa is commonly used 4
• Central access is not required for 3% solutions, though it may be preferred for higher concentrations

Critical warning: 23.4% sodium chloride must be diluted before administration and should only be given through central access 6. Direct injection of concentrated solutions can cause cardiovascular shock, CNS disorders, extensive hemolysis, and cortical necrosis 6.

Monitoring Requirements

Essential monitoring parameters:

• Serum sodium and chloride levels regularly (target Na 145-155 mEq/L) 3
• Serum osmolarity (safe levels up to 364 mOsm/L documented, with individual cases tolerating up to 431 mOsm/L) 3
• Fluid balance (hypertonic saline causes less osmotic diuresis than mannitol) 1
• ICP and cerebral perfusion pressure if monitoring available
• Blood pressure (maintain CPP 60-70 mmHg) 1

Peak sodium levels: Most patients have peak levels <155 mEq/L, though levels up to 169 mEq/L have been documented in survivors without adverse effects 3. Sodium typically returns to normal within 24 hours, most within 4 hours 3.

Safety Profile

Hypertonic saline is remarkably safe when properly monitored 3:

• No evidence of osmotic demyelination syndrome in multiple studies, including autopsy and MRI data 3
• Side effects are primarily hypernatremia and hyperchloremia, both manageable with monitoring 1
• Unlike mannitol, does not cause significant osmotic diuresis requiring volume replacement 1

Key Clinical Considerations

Hypertonic saline should be used INSTEAD OF mannitol, not in combination 3. At equiosmotic doses (250 mOsm), both agents have comparable efficacy for ICP reduction, but hypertonic saline may be superior in patients with:

• Pretreatment hypovolemia
• Hyponatremia
• Renal failure 2

Important limitation: While hypertonic saline effectively reduces ICP (Grade A evidence), it does not improve neurological outcomes or survival in raised ICP states 3. The primary goal is ICP control to prevent herniation and secondary brain injury, not outcome improvement.

Practical Algorithm

1. Confirm indication: Grade 3-4 encephalopathy with suspected raised ICP (altered mental status, signs of herniation like mydriasis/anisocoria)

2. Choose approach:

   • Acute crisis: 250-300 mL of 3% NaCl over 15-20 minutes
   • Sustained management: Continuous 3% NaCl infusion targeting Na 145-155 mEq/L

3. Route: Peripheral IV acceptable for 3% solutions (18-gauge or larger preferred)

4. Monitor: Check sodium/chloride before, at 20 minutes, and 60 minutes post-infusion initially, then every 4-6 hours during continuous infusion

5. Repeat dosing: Can repeat boluses as needed for ICP control; continuous infusions can be maintained for days (mean 7.6 days documented safely) 3

Common Pitfalls to Avoid

• Do not use prophylactically: Hypertonic saline in patients without evidence of intracranial hypertension shows no benefit over crystalloids 1
• Do not delay for central access: Peripheral administration of 3% NaCl is safe and effective 4, 5
• Do not fear osmotic demyelination: This complication has not been documented with hypertonic saline use for ICP management, even with sodium levels >170 mEq/L 3
• Do not combine with mannitol: Use one or the other 3